dextroamphetamine (Dexedrine)
Jump to navigation
Jump to search
Introduction
Tradename: Dexedrine. DEA-controlled substance: class 2.
Indications
- narcolepsy
- adjunctive therapy for attention deficit disorder with hyperactivity
Contraindications
- advanced arteriosclerosis
- hypertension
- hyperthyroidism
- glaucoma
- concurrent administration of MAO inhibitor
Dosage
Tabs: 5 & 10 mg.
Elixir: 5 mg/5 mL. Extended-release: 10-15 mg PO QD
Tabs: 5, 10, 15 mg.
Adverse effects
- common (> 10%)
- arrhythmias
- false sense of well being
- nervousness
- restlessness
- insomnia
- less common (1-10%)
- hypertension, mood or mental changes, blurred vision, changes in libido, diarrhea, nausea/vomiting, stomach cramps, constipation, anorexia, weight loss, dizziness, lightheadedness, headache, dry mouth, increased sweating
- uncommon (< 1%)
- skin rash, hives, chest pain, CNS stimulation (severe), Tourette's syndrome, hyperthermia, seizures, paranoia, tolerance & withdrawal with prolonged use
- sudden death at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems[4]
- reversible cerebral vasoconstriction syndrome
- drug adverse effects of ADHD medications
- drug adverse effects of analeptics
- drug adverse effects of psychotropic agents
- drug adverse effects of sympathomimetic(s)
Laboratory
More general terms
Component of
- aspartate/dextroamphetamine
- amphetamine/dextroamphetamine
- Adderall (dextroamphetamine/racemic amphetamine)
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ 4.0 4.1 MedWatch, Food and Drug Administration http://www.fda.gov/medwatch/safety/2006/safety06.htm#Dexedrine